KGKim Mattos Geraldo

Kim Mattos Geraldo

*This is an algorithmically generated author record based on publicly available information.

Kim Mattos Geraldo has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional Profile of γδ T Cells in Severe and Moderate COVID-19: A Brazilian Cross-Sectional Study

    by Andressa da Silva Cazote, Glenda Domingos Mascarenhas, Hugo Perazzo, Kim Mattos Geraldo, Maria Pia Diniz Ribeiro, Juliana Arruda de Matos, Pedro Emmanuel Alvarenga Americano Do Brasil, Sandra Wagner Cardoso, Beatriz Grinsztejn, Valdiléa Gonçalves Veloso, et al.

    This study aimed to identify the distinct intrinsic response potential of γδ T cells from COVID-19 patients with different illness severities, to better understand the implication of these cells in COVID-19 disease. Forty-four COVID patients were enrolled at hospitalization and classified as: moderate without oxygen support (MWO2; N = 15), moderate with oxygen support (MO2; N = 15), or severe disease requiring mechanical ventilation (SD; N = 14). γδ T cells were characterized ex vivo, isolated from peripheral blood cells, stimulated in vitro with OKT3 and K562 cells, and evaluated for functional markers by flow cytometry. Ex vivo analysis identified 16.21% of total γδ T cells as Vδ1−Vδ2−. SD patients presented a lower frequency of TRAIL+ and of IL-17-producing Vδ2 cells, as well as lower value of fluorescence intensity values for TNF-α in Vδ2 cells, than MWO2 patients (p < 0.05). In addition, paired analyses showed a lower frequency of IL-17-producing than CD161+ Vδ2 cells in SD patients (p < 0.05). These observations suggest a more restricted response potential of the Vδ2 subset in severe disease, show the impact of general immune dysregulation on these cells, or even suggest some role for IL-17-producing Vδ2 cells in preventing critical symptoms.

  • Open Access

    Deep Vein Thrombosis in Critically Ill Patients With COVID ‐19 Pneumonia

    by Clévio Cezar da Fonseca, Hugo Perazzo, Sandra Wagner Cardoso, Isabel Cristina Ferreira Tavares, Maria Pia Diniz Ribeiro, Rodrigo de Carvalho Moreira, Lara Esteves Coelho, Emília Moreira Jalil, André Miguel Japiassú, Elias Pimentel Gouvêa, et al.

    Objectives: The risk of major venous thromboembolism (VTE) among patients with COVID‐19 is high but varies with disease severity. Estimate the incidence of lower extremity deep venous thrombosis (DVT) in critically ill hospitalized patients with COVID‐19, validate the Wells score for DVT diagnosis, and determine patients' prognosis. Methods: This was an observational follow‐up study in the context of the diagnosis and prognosis of DVT. All patients were hospitalized in the intensive care unit (ICU) of the Evandro Chagas National Institute of Infectious Diseases. Participants with COVID‐19 pneumonia were included. Lower‐limb Doppler to assess DVT was performed at admission and follow‐up. Prognosis outcomes were death, length of stay, need for mechanical ventilation, vasopressor use, and hemodialysis. Wells' score sensitivity and specificity were estimated at admission. Survival curves were estimated for patients with DVT and adjusted for the SAPS 3 score. Results: Between June 2020 and January 2021, 186 patients were included. The DVT incidence was 0.097. A Wells score of 2 or higher had a sensitivity and specificity of 1.00 and 0.94, respectively. Mortality and mechanical ventilation support were higher in participants with DVT. For these outcomes, after SAPS 3 adjustment, participants with DVT had twice the hazard of those without DVT. A web calculator ( https://pedrobrasil.shinyapps.io/INDWELL/ ) is available for predictions. Conclusions: One can use the Wells score to accurately diagnose DVT in critically ill patients with COVID‐19. DVT increases the severity of COVID‐19, which highlights the importance of its early diagnosis, treatment, and prophylaxis in the ICU setting.


  • Open Access

    Deep vein thrombosis in critically ill patients with COVID-19: Incidence, Wells score diagnosis validation, and hospital prognosis

    by Clévio Cezar da Fonseca, Hugo Perazzo Pedroso Barbosa, Sandra Wagner Cardoso, Isabel Cristina Ferreira Tavares, Maria Pia Diniz Ribeiro, Rodrigo de Carvalho Moreira, Lara Esteves Coelho, Emília Moreira Jalil, André Miguel Japiassú, Elias Pimentel Gouvêa, et al.

    BACKGROUND: The risk of major venous thromboembolism (VTE) among patients with COVID-19 is high but varies with disease severity. OBJECTIVE: Estimate the incidence of lower extremity deep venous thrombosis (DVT) in critically ill hospitalized patients with COVID-19, validate the Wells score for DVT diagnosis, and determine patient’s prognosis. DESIGN AND SETTING: This was an observational follow-up study in the context of diagnosis and prognosis of DVT. All patients hospitalized in the intensive care unit (ICU) of the Evandro Chagas National Institute of Infectious Diseases. METHODS: Participants with COVID-19 pneumonia were included. Lower-limb Doppler to assess DVT was performed at admission and follow-up. Prognosis outcomes were death, length of stay, need for mechanical ventilation, vasopressor use, and hemodialysis. Wells’ score sensitivity and specificity were estimated at admission. Survival curves were estimated for patients with DVT and adjusted for the SAPS3 score. RESULTS: Between June 2020 and January 2021, 186 patients were included. The DVT incidence was 0.097. A Wells score of two or higher had a sensitivity and specificity of 1.00 and 0.94 respectively. Mortality and mechanical ventilation support were higher in participants with DVT. For these outcomes, after SAPS 3 adjustment, participants with DVT had twice the hazard of those without DVT. A web calculator ( https://pedrobrasil.shinyapps.io/INDWELL/ ) is available for predictions. CONCLUSIONS: One can use the Wells score to accurately diagnose DVT in critically ill patients with COVID-19. DVT increases severity of COVID-19, which highlights the importance of its early diagnosis, treatment, and prophylaxis at the ICU setting.

  • Open Access

    COVID-19 and HIV: Clinical Outcomes and Inflammatory Markers in a Cohort from a Reference Hospital in Rio de Janeiro, Brazil

    by Nathalia Beatriz Ramos de Sá, Karine Venegas Macieira, Mariana Rosa Inacio Coelho, Milena Neira Goulart, Marcelo Ribeiro-Alves, Leonardo Azevedo da Silva Rosadas, Kim Mattos Geraldo, Maria Pia Diniz Ribeiro, Sandra Wagner Cardoso, Beatriz Grinsztejn, et al.

    Background: Severe COVID-19 presents a variety of clinical manifestations associated with inflammatory profiles. People living with HIV (PLWH) could face a higher risk of hospitalization and mortality from COVID-19, depending on their immunosuppression levels. This study describes inflammatory markers in COVID-19 clinical outcomes with and without HIV infection. Methods: We analyzed 112 inpatients of the Hospital Center for COVID-19 (INI/FIOCRUZ), including 22 cases of COVID-19 in PLWH (COVID/PLWH group). Plasma samples were tested for a panel of 15 cytokines by Luminex. Sociodemographic, clinical, and laboratory data were collected from patients’ clinical records. Results: COVID-19 individuals were stratified according to the WHO clinical severity profiles at hospitalization. Significant differences in clinical scores, symptoms (coughs), and the occurrence of HIV infection were found among the groups. Clinical blood parameters and plasma cytokines were analyzed among COVID-19 groups with distinct severity profiles. Critical COVID-19 cases showed higher levels of inflammatory markers (Bilirubin, D-dimer, PCR, and urea, as well as IL-8, IL-10, TNF-α, INF-α, IL-1β, IL-17A, IL-23, IL-6) than moderate and severe groups. The COVID/PLWH group had lower CD4 counts (64 cells/mm3) and cytokine levels than other COVID-19 patients. Conclusions: Overall, critically ill COVID-19 patients exhibited heightened inflammatory responses, while COVID/PLWH demonstrated unique immunological characteristics without increased mortality risk.


  • Open Access

    COVID-19 and HIV: Clinical Outcomes and Inflammatory Markers in a Cohort from a Reference Hospital in Rio de Janeiro, Brazil

    by Nathalia Beatriz Ramos de Sá, Karina Venegas Macieira, Mariana Rosa Inácio Coelho, Milena Neira Goulart, Marcelo Ribeiro-Alves, Leonardo A. S. Rosadas, Kim Mattos Geraldo, Maria Pia Diniz Ribeiro, Sandra Wagner Cardoso, Beatriz Grinsztejn, et al.

    Background: Severe COVID-19 presents a variety of clinical manifestations associated with inflammatory profiles. People living with HIV (PLWH) could face a higher risk of hospitalization and mortality from COVID-19, depending on their immunosuppression levels. This study describes inflammatory markers in COVID-19 clinical outcomes with and without HIV. Methods: We analyzed 112 inpatients of the Hospital Center for COVID-19 (INI/FIOCRUZ), including 22 cases of COVID-19 in PLWH (COVID/PLWH group). Plasma samples were tested for a panel of 15 cytokines by Luminex. Sociodemographic, clinical, and laboratory data were collected from patients’ clinical records. Results: COVID-19 individuals were stratified according to the WHO clinical severity profiles at hospitalization. Significant differences in clinical scores, symptoms (coughs), and the occurrence of HIV infection were found among the groups. Clinical blood parameters and plasma cytokines were analyzed among COVID-19 groups with distinct severity profiles. Critical COVID-19 cases showed higher levels of inflammatory markers (Bilirubin, D-dimer, PCR, and urea, as well as IL-8, IL-10, TNF-α, INF-α, IL-1β, IL-17A, IL-23, IL-6) than moderate and severe groups. The COVID/PLWH group had lower CD4 counts (64 cells/mm3) and cytokine levels than other COVID-19 patients. Conclusion: Overall, critically ill COVID-19 patients exhibited heightened inflammatory responses, while COVID/PLWH demonstrated unique immunological characteristics without increased mortality risk.

  • Open Access

    Inflammasome genes polymorphisms are associated with progression to mechanical ventilation and death in a cohort of hospitalized COVID-19 patients in a reference hospital in Rio de Janeiro, Brazil

    by Milena Neira-Goulart, Nathalia Beatriz Ramos de Sá, Marcelo Ribeiro-Alves, Hugo Perazzo, Kim Mattos Geraldo, Maria Pia Diniz Ribeiro, Sandra Wagner Cardoso, Beatriz Grinsztejn, Valdiléa G. Veloso, Larissa Rodrigues Gomes, et al.


  • Open Access

    Telemedicine as a tool for PrEP delivery during the COVID-19 pandemic in a large HIV prevention service in Rio de Janeiro-Brazil

    by Brenda Hoagland, Thiago S. Torres, Daniel R.B. Bezerra, Kim Geraldo, Cristina Pimenta, Valdilea G. Veloso, Beatriz Grinsztejn